Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to
describe outcomes in children treated with dabigatran etexilate for secondary venous …

Background The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant
effect and may be an alternative therapy to warfarin for patients who have acute venous …

Background Treatment of venous thromboembolism in children is based on data obtained in
adults with little direct documentation of its efficacy and safety in children. The aim of our …

Background Dabigatran, which is administered in a fixed dose and does not require
laboratory monitoring, may be suitable for extended treatment of venous thromboembolism …

It is unclear whether thrombophilia causes resistance to anticoagulant therapy. Post hoc
analyses of data from RE-COVER®, RE-COVER™ II, and RE-MEDY™ were performed to …

Background—Dabigatran and warfarin have been compared for the treatment of acute
venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those …

Abstract Abstract 205 Background: Dabigatran has been compared with warfarin for
treatment of acute venous thromboembolism in one previous trial (RE-COVER). Based on …

Aims The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim
Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double …

The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for
the prophylaxis and treatment of thromboembolic disorders, with three trials completed in …